Literature DB >> 237092

The gas chromatographic determination of atenolol in biological samples.

B Scales, P B Copsey.   

Abstract

Methods are described for the gas chromatographic determination of the B-adrenoceptor blocking agent atenolol (ICI 66,082 Tenormin) in whole blood, serum, tissue and urine. The method involves the extraction of the free base from the prepared biological sample into an organic solvent mixture. Further purification is done by backextracting the base into dilute acid from which, after basification it is extracted again into organic solvent. Any atenolol in the residue remaining after solvent evaporation is converted into a heptafluorobutyrate derivative ready for gas chromatography. Use of an electron-capture detector enables concentrations as low as 0.01 mug ml-minus 1 body fluid and 0.04 mug ml-minus 1 tissue to be measured.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 237092     DOI: 10.1111/j.2042-7158.1975.tb09473.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  28 in total

1.  Separate and combined effects of nadolol and nifedipine on the cardiac response to exercise.

Authors:  M R Wilkins; K L Woods; D B Jack; M J Kendall; S J Laugher
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  Comparison of beta-adrenoceptor blockers under maximal exercise (pindolol v metoprolol v atenolol).

Authors:  J Erikssen; E Thaulow; R Mundal; P Opstad; S Nitter-Hauge
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

3.  Beta-adrenoceptor blockers and the blood-brian barrier.

Authors:  G Neil-Dwyer; J Bartlett; J McAinsh; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

4.  Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol.

Authors:  P Dayer; T Leemann; A Marmy; J Rosenthaler
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects.

Authors:  J W Rigby; A K Scott; G M Hawksworth; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

6.  Transplacental passage of atenolol in man.

Authors:  A Melander; B Niklasson; I Ingemarsson; H Liedholm; B Scherstén; N O Sjöberg
Journal:  Eur J Clin Pharmacol       Date:  1978-11-16       Impact factor: 2.953

7.  Influence of beta-adrenoceptor blocking agents on lymphocyte function in vitro.

Authors:  B Hallengren; A Forsgren; A Melander
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

8.  Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug.

Authors:  F J Conway; J D Fitzgerald; J McAinsh; D J Rowlands; W T Simpson
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

9.  Studies on the pharmacokinetics and pharmacodynamics of atenolol in man.

Authors:  J D Fitzgerald; R Ruffin; K G Smedstad; R Roberts; J McAinsh
Journal:  Eur J Clin Pharmacol       Date:  1978-05-17       Impact factor: 2.953

10.  Diazepam/beta-adrenoceptor antagonist interactions.

Authors:  G Hawksworth; T Betts; A Crowe; R Knight; I Nyemitei-Addo; K Parry; J C Petrie; A Raffle; A Parsons
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.